Lyra Therapeutics Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)
In the latest quarter, 4 analysts provided ratings for Lyra Therapeutics (NASDAQ:LYRA), showcasing a mix of bullish and…
Lyra Therapeutics Implementing Layoff Of ~75% Of Its Workforce
In the near term, Lyra Therapeutics will focus on the two ongoing ENLIGHTEN Phase 3 trials evaluating LYR-210, a bioabsorbable sinonasal implant for the treatment of chronic rhinosinusitis (CRS). Lyra continues to
12 Health Care Stocks Moving In Tuesday’s Intraday Session
Gainers Nuwellis (NASDAQ:NUWE) shares rose 57.7% to $0.27 during Tuesday’s regular session. The company’s market cap stands at…
Where Lyra Therapeutics Stands With Analysts
Analysts’ ratings for Lyra Therapeutics (NASDAQ:LYRA) over the last quarter vary from bullish to bearish, as provided by…
Dow Surges Over 100 Points; EyePoint Pharmaceuticals Shares Plunge
U.S. stocks traded higher toward the end of trading, with the Dow Jones index gaining more than 100…
Crude Oil Gains 1%; TreeHouse Foods Shares Fall After Q1 Results
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 100 points on Monday.…
12 Health Care Stocks Moving In Monday’s Intraday Session
Gainers NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 39.5% to $2.93 during Monday’s regular session. The company’s market cap…
Nasdaq Jumps 100 Points; Tyson Foods Sales Miss Views
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more than 100 points on Monday. The…
Why Lyra Therapeutics Stock Is Down 93% Today
Lyra Therapeutics shares are trading lower by 93% to $0.30 during Monday's session. The company announced the ENLIGHTEN 1 trial did not meet its primary endpoint.
Lyra Therapeutics Reports Topline Results From Phase 3 ENLIGHTEN 1 Trial For LYR-210 in Chronic Rhinosinusitis; ENLIGHTEN 1 Trial Did Not Meet Its Primary Endpoint; Company Plans To Evaluate Full Dataset And Path Forward
ENLIGHTEN 1 trial did not meet its primary endpoint Company plans to evaluate full dataset and path forwardWATERTOWN, Mass., May 06, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (NASDAQ:LYRA) ("Lyra" or the